Symbol="KALV"
AssetType="Common Stock"
Name="Kalvista Pharmaceuticals Inc"
Description="KalVista Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, discovers, develops, and markets small-molecule protease inhibitors for illnesses with unmet needs. The company is headquartered in Cambridge, Massachusetts."
CIK="1348911"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="ONE KENDALL SQUARE, BUILDING 200, STE. 2203, CAMBRIDGE, MA, US"
FiscalYearEnd="April"
LatestQuarter="2023-01-31"
MarketCapitalization="345282000"
EBITDA="-105268000"
PERatio="None"
PEGRatio="0"
BookValue="5.4"
DividendPerShare="0"
DividendYield="0"
EPS="-3.47"
RevenuePerShareTTM="0.214"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.309"
ReturnOnEquityTTM="-0.462"
RevenueTTM="3824000"
GrossProfitTTM="-70167000"
DilutedEPSTTM="-3.47"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.307"
AnalystTargetPrice="19.33"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="107.42"
PriceToBookRatio="0.979"
EVToRevenue="76.33"
EVToEBITDA="-0.246"
Beta="1.031"
num_52WeekHigh="17.06"
num_52WeekLow="4.12"
num_50DayMovingAverage="9.55"
num_200DayMovingAverage="7.7"
SharesOutstanding="34169400"
DividendDate="2016-11-22"
ExDividendDate="None"
symbol="KALV"
open="9.28"
high="10.37"
low="9.25"
price="10.29"
volume="204213.00"
latest_trading_day="2023-07-07"
previous_close="8.95"
change="1.34"
change_percent="14.9721%"
aroon_positive_momentum_days="83"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="83"
Volume_recent_avg="246478"
Change_recent_avg="0.02"
Delta_recent_avg="0.45"
Variance_recent_avg="0.22"
Change_ratio_recent_avg="0.2"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="83"
Aroon_momentum_negative="17"
image_negative_thumbnail_id_1="1090"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0123.jpeg"
image_negative_thumbnail_id_2="137"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0039.jpeg"
image_neutral_thumbnail_id_1="551"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0048.jpeg"
image_neutral_thumbnail_id_2="582"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0017.jpeg"
image_positive_thumbnail_id_1="964"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0126.jpeg"
image_positive_thumbnail_id_2="999"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0161.jpeg"
image_professor_thumbnail_id_1="1177"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0011.jpeg"
image_professor_thumbnail_id_2="1188"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0022.jpeg"
